“The Scientific evidence that supports the effectiveness of our Needlepoint BiPolar Ionisation (NPBI™) against all variants of CoV2 is very robust.
Our viral challenge studies have been thorough with results showing a 99.9% kill of CoV2 and other viruses in actual closed-room validations. I believe that this technology could now seriously reduce airborne transmission of CoV2, influenza and all other viral and bacterial pathogens within contained spaces.
NPBI™ should be listed as one of the key virus control measures for all indoor environments”
Professor Sir Christopher Evans – CEO
